ArticleJournal of insect science (Online)2026
Evaluating efficacy of oxytetracycline, lincomycin, and tylosin for treatment of clinical European foulbrood disease.
Article in Journal of insect science (Online), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Antibiotics have been widely used in North American beekeeping for the last 70 yr, contributing to the emergence of antimicrobial resistance (AMR). European foulbrood (EFB) is a stress-associated, reportedly self-limiting, bacterial disease of honey bee larvae, caused by Melissococcus plutonius (ex-White 1912) Bailey and Collins 1983 (Lactobacillales: Enterococcaceae). Although oxytetracycline (OTC) is the only antibiotic approved for EFB, its continued use in North America requires evidence to justify it, given concerns about AMR despite no confirmed resistance in M. plutonius. Moreover, if AMR emerges in M. plutonius, the efficacy of alternative antimicrobials for treatment of EFB should be determined, such as tylosin (TYL) and lincomycin (LMC), which are approved in North America for managing American foulbrood. Therefore, in this study, we evaluated the effectiveness of OTC, TYL, and LMC in treating colonies affected by a natural outbreak of EFB during spring 2024 in Saskatchewan, Canada. Forty-eight infected colonies were split into 4 groups of 12: 1 sham-treated and 3 treated with either OTC, TYL, or LMC per label instruction. Colony strength and EFB symptoms were monitored over 1 mo, and M. plutonius bacterial load was quantified via Quantitative polymerase chain reaction (qPCR) pretreatment, 1- and 4-wk posttreatment. We found that all antimicrobial-treated colonies had significant improvement in colony strength relative to pretreatment. Adult bees from antimicrobial-treated groups also had a significant reduction in bacterial load 1-mo posttreatment. However, we also observed a spontaneous recovery in sham-treated colonies. Our findings support the clinical efficacy of OTC and highlight the potential of TYL and LMC as effective alternatives for managing EFB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.